✦ LIBER ✦

Suppression of cytophilic antibody (‘arming’ factor) in the sera of patients with prostatic cancer by human seminal plasma

✍ Scribed by R. A. Bhatti; R. J. Ablin; S. Zamora; E. Totonchi; I. M. Bush; P. D. Guinan

Publisher: Springer
Year: 1980
Tongue: English
Weight: 234 KB
Volume: 36
Category: Article
ISSN: 1420-682X
DOI: 10.1007/bf01952320

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Evidence for the presence of an inactive

Evidence for the presence of an inactive precursor of human hepatocyte growth factor in plasma and sera of patients with liver diseases

✍ Naokatu Arakaki; Shuichi Kawakami; Osamu Nakamura; Tomokazu Ohnishi; Hiroomi Miy 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 885 KB

Human hepatocyte growth factor (hHGF), which is now known to be the same protein as the scatter factor and the tumor cytotoxic factor, is a heterodimeric protein with one heavy chain and one light chain linked together by a disulfide bond, and is thought to be involved in liver regeneration. Using a

Detection of a suppressive immunoregulat

Detection of a suppressive immunoregulatory factor (IRF) in the sera of sarcoma patients by enzyme-linked immunoassay (ELISA) and correlation with clinical course

✍ Jack A. Roth 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 689 KB

Immunoregulatory factor (IRF) is a 70,000 molecular weight glycoprotein produced by human tumors that suppresses lymphocyte function including mitogen-stimulated tritiated leucine ('H-leu) and tritiated thymidine (3H-Tdr) uptake, in vitro immunoglobulin synthesis, induction of allospecific cell-medi

Detection of epidermal growth factor rec

Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer

✍ Chen He; Ming Liu; Chengzhi Zhou; Jiexia Zhang; Ming Ouyang; Nanshan Zhong; Jun 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 260 KB 👁 2 views

## Abstract The high frequency of epidermal growth factor receptor (__EGFR__) mutations in tyrosine kinase inhibitor‐responsive non‐small‐cell lung cancer (NSCLC) cases is now well established, highlighting the predictive value of activating __EGFR__ mutations in guiding the clinical use of __EGFR_